Pulse nav.journalClub Tendências Explorar Perguntas Pesquisadores

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Política de privacidade

Início Explorar nav.journalClub Tendências

⌘+K

June 13, 2024

Psychedelics field looks ahead after FDA advisers’ rejection

Key Points

Key points are not available for this paper at this time.

Abstract

Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.

Like

Bookmark

Share

Cite This Study

Kai Kupferschmidt (Thu,) studied this question.

synapsesocial.com/papers/68e64e77b6db6435875deb05 https://doi.org/https://doi.org/10.1126/science.adr0286

Like

Bookmark

Share

Psychedelics field looks ahead after FDA advisers’ rejection | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Psychedelics’ Use as Medicine Hits Significant Roadblock2024
2What’s next for psychedelics after MDMA rejection?2024 · 10 citations
3Reaction mixed over FDA committee rejection of MDMA therapy for PTSD2024
4Much anticipated FDA decision about psychedelics for PTSD ends with denial2024
5FDA publicly releases MDMA rejection letter; MAPS vows to press forward2025